Healthcare investor Wende Hutton brings 23 years of experience to identifying, investing in and building companies that are changing the practice of medicine. She has facilitated bringing over a dozen medical devices and drugs to market, and currently sits on the boards of Antiva Biosciences, Chrono Therapeutics, Glooko, OncoResponse, ReVision Optics and Theraclone Sciences. Prior investments include BiPar Sciences (acquired by Sanofi-aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical) and Transcend Medical (acquired by Alcon/Novartis). Wende was recognized among Fierce Biotech’s 2014 "Fierce 15" women in biotech and honored as one of The Most Influential Women in Bay Area Business 2015 by The San Francisco Business Times.
Wende joined Canaan in 2004, and her life sciences track record includes seven IPOs and six acquisitions. She began her venture career at Mayfield Fund in 1993, where she incubated Heartstream (HPQ) and Northstar Neuroscience (NSTR). Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing.
Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is active with several community service groups including serving on the board of ReSurge International which provides reconstructive surgical care to the needy in developing countries.
2004 - Current (almost 13 years)
|Aug 26, 2016||TechCrunch - Announcing the Disrupt SF Startup Battlefield competition judges|
|Mar 4, 2016||PRNewswire All - Chrono Therapeutics' Smoking Cessation Technology Demonstrates Significant Reduction in Nicotine Cravings|
|Jan 13, 2016||Bloomberg - At Biotech Party, Gender Diversity Means Cocktail Waitresses|
|Jun 29, 2015||Xconomy - Out of the Digital Health Fog, More Investments Are Coming in 2015|
|May 7, 2015||CNet - Women venture capitalists say to hell with the status quo - CNET|
|Mar 18, 2015||eWeek - Glooko Raises $16.5 Million for Diabetes Management Platform|
|Mar 17, 2015||TechCrunch - Glooko Gets $16.5M Injection For Its Diabetes Management Platform|
|Mar 17, 2015||Mass Device - Diabetes: Medtronic gets in on $17m Series B for Glooko|